Patents by Inventor Olaf Panknin

Olaf Panknin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10442772
    Abstract: The present invention relates to benzimidazol-2-amines of general formula (I), in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: October 15, 2019
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Hartmut Rehwinkel, Olaf Panknin, Sven Ring, Sonja Anlauf, Holger Siebeneicher, Duy Nguyen, Wolfgang Schwede, Marcus Bauser, Katja Zimmermann, Stefan Kaulfuss, Roland Neuhaus, Paul Matthew Blaney
  • Patent number: 10414734
    Abstract: The present invention relates to benzimidazol-2-amines of general formula (I) in which R1, R2, R3, R4, R5, R6 and R7 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: July 12, 2016
    Date of Patent: September 17, 2019
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Olaf Panknin, Sven Ring, Katja Zimmermann, Roland Neuhaus
  • Patent number: 10370339
    Abstract: The present invention relates to benzimidazol-2-amines of general formula (I), in which R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: August 6, 2019
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Sven Ring, Olaf Panknin, Katja Zimmermann, Judith Günther, Lars Bärfacker
  • Publication number: 20190083659
    Abstract: A compound having the formula of tetragadolinium [4,10-bis(carboxylatomethyl)-7-{-3,6,12,15-tetraoxo-16-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]-9,9-bis({[{2-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]propanoyl} amino)acetyl]amino}methyl)-4,7,11,14-tetraazaheptadecan-2-yl}-1,4,7,10-tetraazacyclo dodecan-1-yl]acetate wherein the stereochemistry at the chiral carbon of the four alanine substituents is selected from the group consisting of RRRR, SSSS, RSSS, RRSS, and RRRS stereoisomers, and racemic and diastereomeric mixtures of any thereof, or a tautomer, a hydrate, a solvate, or a salt thereof, or a mixture of same is described. The compounds may be used as an MRI contrast imaging agent.
    Type: Application
    Filed: November 15, 2018
    Publication date: March 21, 2019
    Inventors: Markus Berger, Jessica Lohrke, Christoph-Stephan Hilger, Gregor Jost, Thomas Frenzel, Detlev Suelzle, Johannes Platzek, Olaf Panknin, Hubertus Pietsch
  • Publication number: 20190062285
    Abstract: The present invention relates to benzimidazol-2-amines of general formula (I), in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: March 16, 2018
    Publication date: February 28, 2019
    Inventors: Hartmut REHWINKEL, Olaf Panknin, Sven Ring, Sonja Anlauf, Holger Siebeneicher, Duy Nguyen, Wolfgang Schwede, Marcus Bauser, Katja Zimmermann, Stefan Kaulfuss, Roland Neuhaus, Paul Matthew Blaney
  • Patent number: 10179123
    Abstract: The present invention relates to 2-Aryl- and 2-Arylalkyl-benzimidazoles of general formula (I): in which A, R1, R4, R5, R6, R7, R8, R9, R10 and R11 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: July 4, 2016
    Date of Patent: January 15, 2019
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Olaf Panknin, Katja Zimmermann, Roland Neuhaus
  • Patent number: 10137209
    Abstract: The present invention relates to a new class of high relaxivity extracellular gadolinium chelate complexes, to methods of preparing said compounds, and to the use of said compounds as MRI contrast agents.
    Type: Grant
    Filed: May 30, 2016
    Date of Patent: November 27, 2018
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Markus Berger, Jessica Lohrke, Christoph-Stephan Hilger, Gregor Jost, Thomas Frenzel, Detlev Suelzle, Johannes Platzek, Olaf Panknin, Hubertus Pietsch
  • Patent number: 10137110
    Abstract: The present invention relates to benzimidazol-2-amines of general formula (I) in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: October 21, 2015
    Date of Patent: November 27, 2018
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Hartmut Rehwinkel, Sonja Anlauf, Duy Nguyen, Olaf Panknin, Marcus Bauser, Katja Zimmermann, Stefan Kaulfuss, Roland Neuhaus, Paul Matthew Blaney, Gianna Toschi
  • Publication number: 20180215717
    Abstract: The present invention relates to compounds of general formula (I): in which R1, R2, R3, R4, R6, R7, R8, R9, R10, R11, R12, R13 and X are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: July 14, 2016
    Publication date: August 2, 2018
    Applicant: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Olaf PANKNIN, Ingo HARTUNG, Hartmut REHWINKEL, Duy NGUYEN, Ludwig ZORN, Petra HELFRICH, Katja ZIMMERMANN, Roland NEUHAUS
  • Publication number: 20180207137
    Abstract: The present invention relates to 2-Aryl- and 2-Arylalkyl-benzimidazoles of general formula (I): in which A, R1, R4, R5, R6, R7, R8, R9, R10 and R11 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: July 4, 2016
    Publication date: July 26, 2018
    Applicant: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Olaf PANKNIN, Katja ZIMMERMANN, Roland NEUHAUS
  • Publication number: 20180201585
    Abstract: The present invention relates to benzimidazol-2-amines of general formula (I) in which R1, R2, R3, R4, R5, R6 and R7 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: July 12, 2016
    Publication date: July 19, 2018
    Applicant: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Olaf PANKNIN, Sven RING, Katja ZIMMERMANN, Roland NEUHAUS
  • Publication number: 20180170882
    Abstract: The present invention relates to benzimidazol-2-amines of general formula (I), in which R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: June 3, 2016
    Publication date: June 21, 2018
    Applicant: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Sven RING, Olaf PANKNIN, Katja ZIMMERMANN, Judith GÜNTHER, Lars BÄRFACKER
  • Publication number: 20180169274
    Abstract: The present invention relates to a new class of high relaxivity extracellular gadolinium chelate complexes, to methods of preparing said compounds, and to the use of said compounds as MRI contrast agents.
    Type: Application
    Filed: May 30, 2016
    Publication date: June 21, 2018
    Inventors: MARKUS BERGER, JESSICA LOHRKE, CHRISTOPH-STEPHAN HILGER, GREGOR JOST, THOMAS FRENZEL, DETLEV SUELZLE, JOHANNES PLATZEK, OLAF PANKNIN, HUBERTUS PIETSCH
  • Patent number: 9957235
    Abstract: The present invention relates to benzimidazol-2-amines of general formula (I), in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: February 10, 2015
    Date of Patent: May 1, 2018
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Hartmut Rehwinkel, Olaf Panknin, Sven Ring, Sonja Anlauf, Holger Siebeneicher, Duy Nguyen, Wolfgang Schwede, Marcus Bauser, Katja Zimmermann, Stefan Kaulfuss, Roland Neuhaus, Paul Matthew Blaney
  • Patent number: 9951027
    Abstract: The present invention relates to benzimidazol-2-amines of general formula (I): in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: February 10, 2015
    Date of Patent: April 24, 2018
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Hartmut Rehwinkel, Holger Siebeneicher, Sonja Anlauf, Duy Nguyen, Olaf Panknin, Sven Ring, Wolfgang Schwede, Marcus Bauser, Katja Zimmermann, Stefan Kaulfuss, Roland Neuhaus
  • Publication number: 20170319549
    Abstract: The present invention relates to benzimidazol-2-amines of general formula (I) in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: October 21, 2015
    Publication date: November 9, 2017
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Hartmut REHWINKEL, Sonja ANLAUF, Duy NGUYEN, Olaf PANKNIN, Marcus BAUSER, Katja ZIMMERMANN, Stefan KAULFUSS, Roland NEUHAUS, Paul Matthew BLANEY, Gianna TOSCHI
  • Publication number: 20170197922
    Abstract: The present invention relates to benzimidazol-2-amines of general formula (I): in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: February 10, 2015
    Publication date: July 13, 2017
    Inventors: Hartmut REHWINKEL, Holger SIEBENEICHER, Sonja ANLAUF, Duy NGUYEN, Olaf PANKNIN, Sven RING, Wolfgang SCHWEDE, Marcus BAUSER, Katja ZIMMERMANN, Stefan KAULFUSS, Roland NEUHAUS
  • Publication number: 20170197921
    Abstract: The present invention relates to benzimidazol-2-amines of general formula (I), in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: February 10, 2015
    Publication date: July 13, 2017
    Inventors: Hartmut REHWINKEL, Olaf PANKNIN, Sven RING, Sonja ANLAUF, Holger SIEBENEICHER, Duy NGUYEN, Wolfgang SCHWEDE, Marcus BAUSER, Katja ZIMMERMANN, Stefan KAULFUSS, Roland NEUHAUS, Paul Matthew BLANEY
  • Publication number: 20160052936
    Abstract: Spiroindoline derivatives, processes for their preparation and pharmaceutical compositions thereof, their use for the treatment of diseases, and their use for the manufacture of medicaments for the treatment of diseases, especially sex-hormone-related diseases in both men and women, in particularly those selected from the group of endometriosis, uterine leiomyoma (fibroids), polycystic ovarian disease, menorrhagia, dysmenorrhea, hirsutism, precocious puberty, gonadal steroid-dependent neoplasia such as cancers of the prostate, breast and ovary, gonadotrope pituitary adenomas, sleep apnea, irritable bowel syndrome, premenstrual syndrome, benign prostatic hypertrophy, contraception, infertility and assisted reproductive therapy such as in vitro fertilization. The present application relates in particular to spiroindoline derivatives as gonadotropin-releasing hormone (GnRH) receptor antagonists.
    Type: Application
    Filed: April 8, 2014
    Publication date: February 25, 2016
    Applicant: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Olaf PANKNIN, Sven RING, Stefan BÄURLE, Andrea WAGENFELD, Reinhard NUBBEMEYER, Katrin NOWAK-REPPEL, Gernot LANGER
  • Publication number: 20140357655
    Abstract: Spiroindoline derivatives, process for their preparation and pharmaceutical compositions thereof, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially sex-hormone-related diseases in both men and women, in particularly those selected from the group of endometriosis, uterine fibroids, polycystic ovarian disease, hirsutism, precocious puberty, gonadal steroid-dependent neoplasia such as cancers of the prostate, breast and ovary, gonadotrope pituitary adenomas, sleep apnea, irritable bowel syndrome, premenstrual syndrome, benign prostatic hypertrophy, contraception and infertility (e.g., assisted reproductive therapy such as in vitro fertilization). The present application relates in particular to spiroindoline derivatives as gonadotropin-releasing hormone (GnRH) receptor antagonists.
    Type: Application
    Filed: January 15, 2013
    Publication date: December 4, 2014
    Inventors: Olaf Panknin, Stefan Bäurle, Sven Ring, Wolfgang Schwede, Wilhelm Bone, Katrin Nowak-Reppel, Eckhard Bender, Reinhard Nubbemeyer, Mark Jean Gnoth